Jindřich Činátl

26.3k total citations · 2 hit papers
352 papers, 13.4k citations indexed

About

Jindřich Činátl is a scholar working on Molecular Biology, Epidemiology and Immunology. According to data from OpenAlex, Jindřich Činátl has authored 352 papers receiving a total of 13.4k indexed citations (citations by other indexed papers that have themselves been cited), including 148 papers in Molecular Biology, 91 papers in Epidemiology and 71 papers in Immunology. Recurrent topics in Jindřich Činátl's work include Cytomegalovirus and herpesvirus research (55 papers), Neuroblastoma Research and Treatments (48 papers) and SARS-CoV-2 and COVID-19 Research (30 papers). Jindřich Činátl is often cited by papers focused on Cytomegalovirus and herpesvirus research (55 papers), Neuroblastoma Research and Treatments (48 papers) and SARS-CoV-2 and COVID-19 Research (30 papers). Jindřich Činátl collaborates with scholars based in Germany, United Kingdom and United States. Jindřich Činátl's co-authors include Martin Michaelis, Hans Wilhelm Doerr, Roman A. Blaheta, Holger F. Rabenau, H. W. Doerr, Florian Rothweiler, Denisa Bojková, Sandra Ciesek, Martin Scholz and Jaroslav Činátl and has published in prestigious journals such as Nature, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jindřich Činátl

343 papers receiving 13.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

2020 642 citations Denisa Bojková, Kevin Klann et al. Nature profile →
Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective against H5N1 and H1N1 Recovered from Human IgM+ Memory B Cells

2008 596 citations Jindřich Činátl et al. PLoS ONE profile →

Peers

Countries citing papers authored by Jindřich Činátl

Since Specialization

Citations

This map shows the geographic impact of Jindřich Činátl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jindřich Činátl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jindřich Činátl more than expected).

Fields of papers citing papers by Jindřich Činátl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jindřich Činátl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jindřich Činátl. The network helps show where Jindřich Činátl may publish in the future.

Co-authorship network of co-authors of Jindřich Činátl

This figure shows the co-authorship network connecting the top 25 collaborators of Jindřich Činátl. A scholar is included among the top collaborators of Jindřich Činátl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jindřich Činátl. Jindřich Činátl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased efficacy of PARP inhibitors against cisplatin-sensitive and -resistant ovarian cancer cells mediated via ATR and ATM inhibition 2025 ·Cell Death Discovery ·(unknown), (unknown), (unknown), (unknown), Jindřich Činátl, Martin Michaelis, Gerd Bendas	0
2	Precision targeting of rhabdomyosarcoma by combining primary CAR NK cells and radiotherapy 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), Tobias Bexte, (unknown), (unknown), Stephanie Hehlgans, (unknown), Florian Rothweiler, Jindřich Činátl, Martin Michaelis, Halvard Bönig, Elise Gradhand, Meike Vogler, Franz Rödel, Winfried S. Wels, Evelyn Ullrich	0
3	Sulforaphane Inhibits Adhesion and Migration of Cisplatin- and Gemcitabine-Resistant Bladder Cancer Cells In Vitro 2024 ·Nutrients ·Hui Xie, Jochen Rutz, Sebastian Maxeiner, (unknown), Anita Thomas, Eva Juengel, Felix K.‐H. Chun, Jindřich Činátl, Axel Haferkamp, Igor Tsaur, Roman A. Blaheta	3
4	Loss of Key EMT-Regulating miRNAs Highlight the Role of ZEB1 in EGFR Tyrosine Kinase Inhibitor-Resistant NSCLC 2023 ·International Journal of Molecular Sciences ·(unknown), (unknown), (unknown), (unknown), Stefan Holdenrieder, Martin Michaelis, Jindřich Činátl, Christoph A. Ritter	9
5	Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma 2023 ·British Journal of Cancer ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Melanie Demes, (unknown), Yannick Braun, Elise Gradhand, Florian Rothweiler, Martin Michaelis, Jindřich Činátl, Meike Vogler	9
6	SARS-CoV-2 Variants Show Different Host Cell Proteome Profiles With Delayed Immune Response Activation in Omicron-Infected Cells 2023 ·Molecular & Cellular Proteomics ·(unknown), (unknown), Kevin Klann, Katharina Grikscheit, Denisa Bojková, Jindřich Činátl, Georg Tascher, Sandra Ciesek, Christian Münch	2
7	Functional Downregulation of PD-L1 and PD-L2 by CpG and non-CpG Oligonucleotides in Melanoma Cells 2022 ·Cancers ·Johannes Kleemann, (unknown), (unknown), Nadja Zöller, Jindřich Činátl, (unknown), Roland Kaufmann, Markus Meißner, Stefan Kippenberger	3
8	Development and optimization of a high‐throughput screening assay for in vitro anti‐SARS‐CoV‐2 activity: Evaluation of 5676 Phase 1 Passed Structures 2022 ·Journal of Medical Virology ·Winston Chiu, (unknown), Christel Van den Eynde, Christophe Buyck, Sandra De Meyer, Dirk Jochmans, Denisa Bojková, Sandra Ciesek, Jindřich Činátl, Steven De Jonghe, Pieter Leyssen, Johan Neyts, Marnix Van Loock, Ellen Van Damme	12
9	The routine use of LCD-Array hybridisation technique for HPV subtyping in the diagnosis of penile carcinoma compared to other methods 2022 ·BMC Urology ·Ria Winkelmann, Katrin Bankov, Jens von der Grün, Jindřich Činátl, Peter J. Wild, Stefan Vallo, Melanie Demes	0
10	Biochemical characterization of protease activity of Nsp3 from SARS-CoV-2 and its inhibition by nanobodies 2021 ·PLoS ONE ·Lee A. Armstrong, Sven M. Lange, Virginia De Cesare, S. Matthews, Raja Sekhar Nirujogi, (unknown), Anthony G. Hope, Fraser Cunningham, Rachel Toth, Rukmini Mukherjee, Denisa Bojková, Franz Gruber, David W. Gray, Paul G. Wyatt, Jindřich Činátl, Ivan Đikić, Paul Davies, Yogesh Kulathu	51
11	A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection 2021 ·Scientific Data ·Bernhard Ellinger, Denisa Bojková, Andrea Zaliani, Jindřich Činátl, Carsten Claussen, Sandra Westhaus, Oliver Keminer, Jeanette Reinshagen, Maria Kuzikov, Markus Wolf, Gerd Geißlinger, Philip Gribbon, Sandra Ciesek	52
12	Constitutive Cell Proliferation Regulating Inhibitor of Protein Phosphatase 2A (CIP2A) Mediates Drug Resistance to Erlotinib in an EGFR Activating Mutated NSCLC Cell Line 2021 ·Cells ·(unknown), (unknown), Robin Michelet, (unknown), (unknown), Stefan Holdenrieder, (unknown), Mark N. Wass, Jindřich Činátl, Martin Michaelis, Charlotte Kloft, Christoph A. Ritter	9
13	Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection 2021 ·Journal of Biological Chemistry ·Rukmini Mukherjee, Anshu Bhattacharya, Denisa Bojková, Ahmad Reza Mehdipour, Dong Hyuk Shin, Khadija Shahed Khan, (unknown), Kam‐Bo Wong, Wai‐Lung Ng, Jindřich Činátl, Paul P. Geurink, Gerbrand J. van der Heden van Noort, Krishnaraj Rajalingam, Sandra Ciesek, Gerhard Hummer, Ivan Đikić	40
14	Proteomics of SARS-CoV-2-infected host cells reveals therapy targets breakdown → 2020 ·Nature ·Denisa Bojková, Kevin Klann, Benjamin Koch, Marek Widera, David Krause, Sandra Ciesek, Jindřich Činátl, Christian Münch	642
15	Intact-Cell MALDI-ToF Mass Spectrometry for the Authentication of Drug-Adapted Cancer Cell Lines 2019 ·Cells ·Jane F. Povey, (unknown), Adewale Victor Aderemi, Florian Rothweiler, Richard Zehner, Wilhelm G. Dirks, Jindřich Činátl, Andrew J. Racher, Mark N. Wass, C. Mark Smales, Martin Michaelis	3
16	The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1 2018 ·Proceedings of the National Academy of Sciences ·Kirsten M. Knecht, Olga Buzovetsky, Constanze Schneider, Dominique Thomas, Vishok Srikanth, Lars Kaderali, Florentina Tofoleanu, Krystle Reiss, Nerea Ferreirós, Gerd Geißlinger, Víctor S. Batista, Xiaoyun Ji, Jindřich Činátl, Oliver T. Keppler, Yong Xiong	24
17	BAG3 Overexpression and Cytoprotective Autophagy Mediate Apoptosis Resistance in Chemoresistant Breast Cancer Cells 2018 ·Neoplasia ·Chandan Kanta Das, Benedikt Linder, Florian Bonn, Florian Rothweiler, Ivan Đikić, Martin Michaelis, Jindřich Činátl, Mahitosh Mandal, Donat Kögel	74
18	Synthetic lethal hubs associated with vincristine resistant neuroblastoma 2010 ·Molecular BioSystems ·(unknown), Susanne Barth, Tsviya Olender, Andreea Munteanu, Andreas Bernthaler, (unknown), Paul Perco, Arno Lukas, Doron Lancet, Jindřich Činátl, Martin Michaelis, Bernd Mayer	8
19	Reversal of P-glycoprotein–Mediated Multidrug Resistance by the Murine Double Minute 2 Antagonist Nutlin-3 2009 ·Cancer Research ·Martin Michaelis, Florian Rothweiler, (unknown), Andreas von Deimling, Kristoffer Weber, Boris Fehse, Bernd Kammerer, Hans Wilhelm Doerr, Jindřich Činátl	83
20	Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization. 2005 ·PubMed ·(unknown), Aleš Vícha, Marie Jarošová, (unknown), Jindřich Činátl, Martin Michaelis, Tomáš Eckschlager	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact